These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 2888554

  • 1. The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones.
    George SR, Hegele RA, Burrow GN.
    Clin Invest Med; 1987 Jul; 10(4):309-15. PubMed ID: 2888554
    [Abstract] [Full Text] [Related]

  • 2. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF, van Liessum PA, Smals AG, van Gennep JA, Benraad TJ, Kloppenborg PW.
    Acta Endocrinol Suppl (Copenh); 1987 Jul; 286():9-18. PubMed ID: 2892339
    [Abstract] [Full Text] [Related]

  • 3. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
    Williams G, Anderson JV, Williams SJ, Bloom SR.
    Acta Endocrinol Suppl (Copenh); 1987 Jul; 286():26-36. PubMed ID: 2892335
    [Abstract] [Full Text] [Related]

  • 4. Dissociated effects of somatostatin analogs on arginine-induced insulin, glucagon and growth hormone release in acromegalic patients.
    Wajchenberg BL, Cesar FP, Leme CE, Borghi VC, Souza VC, Souza IT, Neto DG, Germek OA, Coy DH, Comaru-Schally AM.
    Horm Metab Res; 1983 Oct; 15(10):471-4. PubMed ID: 6139329
    [Abstract] [Full Text] [Related]

  • 5. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
    Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E.
    Lancet; 1984 Oct 06; 2(8406):782-4. PubMed ID: 6148524
    [Abstract] [Full Text] [Related]

  • 6. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.
    Lamberts SW, Oosterom R, Neufeld M, del Pozo E.
    J Clin Endocrinol Metab; 1985 Jun 06; 60(6):1161-5. PubMed ID: 2860119
    [Abstract] [Full Text] [Related]

  • 7. Reduced postprandial hyperglycemia after subcutaneous injection of a somatostatin-analogue (SMS 201-995) in insulin-dependent diabetes mellitus.
    Spinas GA, Bock A, Keller U.
    Diabetes Care; 1985 Jun 06; 8(5):429-35. PubMed ID: 2865093
    [Abstract] [Full Text] [Related]

  • 8. [The effects of somatostatin in acromegaly].
    Schaison G, Roger M, Milhaud G.
    Nouv Presse Med; 1976 Mar 06; 5(10):629-32. PubMed ID: 772591
    [Abstract] [Full Text] [Related]

  • 9. Improvement of diabetes after treatment with somatostatin analogue SMS 201-995 in an acromegalic patient.
    Cantalamessa L, Catania A, Baldini M, Orsatti A.
    Horm Metab Res; 1986 Nov 06; 18(11):790-1. PubMed ID: 2878866
    [Abstract] [Full Text] [Related]

  • 10. Differences between somatostatin-28 and somatostatin-14 with respect to their biological effects in healthy humans and acromegalics.
    Hadjidakis DJ, Raptis SA, Souvatzoglou A, Karaiskos C, Diamantopoulos EJ, Moulopoulos SD.
    Clin Physiol Biochem; 1986 Nov 06; 4(6):372-83. PubMed ID: 2880690
    [Abstract] [Full Text] [Related]

  • 11. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
    Chiodini PG, Cozzi R, Dallabonzana D, Oppizzi G, Verde G, Petroncini M, Liuzzi A, del Pozo E.
    J Clin Endocrinol Metab; 1987 Mar 06; 64(3):447-53. PubMed ID: 2880861
    [Abstract] [Full Text] [Related]

  • 12. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
    Lamberts SW, Zweens M, Verschoor L, del Pozo E.
    J Clin Endocrinol Metab; 1986 Jul 06; 63(1):16-9. PubMed ID: 2872225
    [Abstract] [Full Text] [Related]

  • 13. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).
    Barnard LB, Grantham WG, Lamberton P, O'Dorisio TM, Jackson IM.
    Ann Intern Med; 1986 Dec 06; 105(6):856-61. PubMed ID: 2877605
    [Abstract] [Full Text] [Related]

  • 14. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995.
    Williams G, Ball JA, Burrin JM, Joplin GF, Bloom SR.
    Lancet; 1986 Oct 04; 2(8510):774-8. PubMed ID: 2876235
    [Abstract] [Full Text] [Related]

  • 15. Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995).
    Sandler LM, Burrin JM, Williams G, Joplin GF, Carr DH, Bloom SR.
    Clin Endocrinol (Oxf); 1987 Jan 04; 26(1):85-95. PubMed ID: 2879656
    [Abstract] [Full Text] [Related]

  • 16. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
    van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW.
    Clin Endocrinol (Oxf); 2005 Aug 04; 63(2):176-84. PubMed ID: 16060911
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P, Wang Y, van der Hoek J, Nedelman J, Schran H, Tran LL, Lamberts SW.
    Clin Pharmacol Ther; 2005 Jul 04; 78(1):69-80. PubMed ID: 16003295
    [Abstract] [Full Text] [Related]

  • 18. Somatostatin octapeptide (SMS 201-995) in the medical treatment of acromegaly.
    Wass JA, Lytras N, Besser GM.
    Scand J Gastroenterol Suppl; 1986 Jul 04; 119():136-40. PubMed ID: 2876497
    [Abstract] [Full Text] [Related]

  • 19. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
    Williams G, Füessl HS, Burrin JM, Chilvers E, Bloom SR.
    Horm Metab Res; 1988 Mar 04; 20(3):168-70. PubMed ID: 2898427
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacodynamic analysis of octreotide in acromegalic patients.
    Comets E, Mentré F, Grass P, Kawai R, Marbach P, Vonderscher J.
    Clin Pharmacol Ther; 2003 Jan 04; 73(1):95-106. PubMed ID: 12545148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.